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Abstract Disclosure of HIV status to family, friends, and a
stable partner may be linked to improved health outcomes
for people living with HIV. This study assessed whether
non-disclosure is associated with psychological symptoms,
non-adherence to antiretroviral therapy (ART), and viral
load (VL) non-suppression. A total of 3258 HIV-diagnosed
individuals in the UK completed the confidential ASTRA
study questionnaire (2011–2012). Participants reported
whether they told anyone they had HIV; to which confi-
dant(s) (friends, family, work colleagues, stable partner)
and to what extent (none, some, most/all). The prevalence
and factors associated with non-disclosure were assessed.
Associations between non-disclosure and the following
factors were established using modified Poisson regression
with adjustment for socio-demographic factors (gender,
age group, ethnicity), HIV-related factors (time since HIV
diagnosis, ART status), and clinic: low social support
(score B 12 on modified Duke-UNC FSSQ); depression
and anxiety symptoms (C10 on PHQ-9 and GAD-7
respectively); self-reported ART non-adherence in past
2 weeks/3 months; VL non-suppression (clinic-recorded
VL[ 50 copies/mL among those who started ART C 6
months ago). Among 3233 participants with disclosure
data, the prevalence of non-disclosure to anyone was
16.6 % (n/N = 61/367) among heterosexual men, 15.7 %
(98/626) among women, and 5.0 % (113/2240) among
MSM. MSM were more likely to disclose to some/all
friends compared to family (85.8 vs. 59.9 %) while
heterosexuals were less likely to disclose to friends than
family (44.1 vs. 61.1 % for men, 57.5 vs. 67.1 % for
women). Among 1,631 participants with a stable partner,
non-disclosure to a stable partner was 4.9 % for MSM,
10.9 % for heterosexual men, and 13.0 % for women. In
adjusted analyses, older age (C60 years), non-white eth-
nicity, more recent HIV diagnosis, and not having a
stable partner were significantly associated with overall
non-disclosure for MSM and heterosexual individuals. The
prevalence of low social support was 14.4 %, of depression
and anxiety symptoms 27.1 and 22.0 %, respectively, of
ART non-adherence 31.8 %, and of viral load non-sup-
pression on ART 9.8 %. There was no evidence that non-
disclosure overall (versus disclosure to anyone) was asso-
ciated with low social support, depression or anxiety
symptoms, ART non-adherence or VL non-suppression
among MSM or heterosexual individuals. However, com-
pared to MSM who disclosed to ‘none’ or ‘some’ friends
and family, MSM who disclosed to ‘most or all’ of their
friends and family were more likely to have symptoms of
depression (adjusted PR = 1.4, 95 % CI 1.2–1.7), anxiety
(1.3, 1.1–1.6), and to report ART non-adherence (1.3,
1.1–1.5). In this large multicentre study of people living
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with HIV in the UK, non-disclosure was overall low, but
higher for heterosexual individuals compared to MSM.
Non-disclosure was not associated with higher prevalence
of adverse health measures.
Keywords HIV  Antiretroviral  Adherence  Disclosure 
Social support
Introduction
Disclosure of HIV status to family and friends is a selective
and often planned behaviour, which balances risks and
benefits [1]. Important deterrents of disclosure include the
lack of a social network [2], fears of stigma and abuse [2–4],
subsequent disclosure of stigmatised behaviours (sexual
orientation, injecting drug use), fear of conflicts with a
partner [5, 6], loss of social support, breach of confiden-
tiality [2], and the need to not burden family members with
one’s health issues [2, 7]. Additionally, HIV positive people
may need time to come to terms with their own diagnosis or
may feel their health is a private matter [7, 8]. Although
these responses are common, disclosure may also provide a
way of obtaining social and psychological support to
overcome a diagnosis that is in many ways more complex
than other chronic conditions [9].
Over the last decade, UK studies among HIV-outpatient
clinic attendees showed that the prevalence of non-disclo-
sure is lower among MSM compared to heterosexual
individuals [2, 10–12]. Economic and educational disad-
vantage along with belonging to a racial/ethnic minority
were associated with higher prevalence of non-disclosure
in UK and US studies [1, 2, 9, 11–14]. Compared to MSM,
black African heterosexuals in the UK have been shown to
have higher non-disclosure rates overall, and particularly
for non-disclosure to their stable partner [6, 11, 14]. Non-
disclosure to a stable partner differs from non-disclosure in
the social context as such a partnership usually involves a
sexual relationship and concerns about the potential risk of
HIV transmission. Additionally, disclosure within a rela-
tionship could be associated with a closer and more trusting
relationship and improved social support [2].
Although studies show a significant minority of people
with HIV choose to not disclose their status to family and
friends and/or partners, the extent to which such non-dis-
closure impacts on psychological health, ability to adhere
to antiretroviral treatments (ART), and virological outcome
of ART is unclear. Associations of non-disclosure with
depression or anxiety may be mediated by low social
support [3]. While HIV status disclosure has been seen as
an important step towards enhancing mental health through
increased social support [15], evidence remains mixed
[11, 12, 14, 16].
Evidence for a link between non-disclosure and non-
adherence to ART is also limited. The relationship is likely
to be dependent on specific socio-demographic groups
surveyed, availability of ART, health care-related factors,
and level of engagement in HIV care [17–21]. Thus, the
implications of non-disclosure of HIV status with regards
to ART adherence and virological outcomes may be dif-
ferent in the current era of simpler treatments and excellent
prognosis for HIV.
This paper presents data from a large multicentre study
of HIV-diagnosed people in the UK, which aimed to (1)
determine the prevalence of non-disclosure within the
social network (family, friends, co-workers) and to a
current stable partner, (2) establish associations of socio-
demographic and HIV-related factors with prevalence of
non-disclosure in the social network and to a stable part-
ner, and (3) examine associations of non-disclosure with:
low social support, psychological symptoms, non-adher-
ence to ART, and viral load non-suppression among those
on ART.
Methods
ASTRA Study
The Antiretrovirals Sexual Transmission Risks and Atti-
tudes (ASTRA) study recruited men and women with
diagnosed HIV infection attending one of eight UK HIV
outpatient clinics during 2011–2012 [22]. Participants
completed a confidential, gender-specific questionnaire that
included socio-demographic information (gender, sexual
orientation, age, ethnicity, education, employment, reli-
gion, stable partner, social support), HIV-related factors
(date of HIV diagnosis, ART use, ART adherence), mental
health symptoms (anxiety, depression). Clinic-recorded
viral load (VL) and CD4 count were documented for all
participants (the latest value communicated to the partici-
pant). Low functional social support (lack of a supportive
social network) was defined as a total score of 12 or less on
the modified Duke-UNC FSSQ [23]. (ebox1 Supplemen-
tary Material) Depression and anxiety symptoms were
defined as scores of 10 or higher on the PHQ-9 and GAD-
7, respectively [24, 25]. ART non-adherence was defined
(among those on ART) as missing one or more doses of
ART in the previous two weeks or more than two con-
secutive days of ART on one or more occasions in the
previous 3 months. Viral load non-suppression was defined
as clinic-recorded VL[ 50 copies/mL among those who
had started ART at least 6 months prior to the VL measure.
Participants were asked if they were currently in an on-
going relationship with a partner, defined as a wife/hus-
band, civil partner, or girlfriend/boyfriend. They also
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provided information on the current partner’s HIV status,
length of time in the relationship, and cohabitation.
Disclosure in a Social Context
Participants were asked whether they had told anyone apart
from health care staff that they have HIV. If they answered
‘‘Yes’’, they specified whether they had told family mem-
bers, friends and, if applicable, work colleagues, or a
stable partner (see below disclosure to stable partner/
spouse). If participants had not disclosed to anyone in these
categories they were classified as not having disclosed to
anyone in a social context.
Disclosure to Family/Friends
Among those who indicated having disclosed to at least
one person, participants specified whether they told
‘‘none’’, ‘‘some’’, or ‘‘most or all’’ family members or
friends. A combined variable (‘disclosure to friends and
family’) was defined with three categories; ‘‘none’’, if
participants had not disclosed to any friends or family,
‘‘most or all’’ if participants disclosed to ‘‘most or all’’ of
their friends and ‘‘most or all’’ of their family members and
‘‘some’’ otherwise (for full details see Table 1).
Disclosure to Stable Partner/Spouse
Non-disclosure to a stable partner was defined as a ‘‘No’’ to
the question ‘‘I have told a partner/wife/husband that I have
HIV’’ and was assessed only among those who indicated
being in an ongoing relationship with a partner.
Disclosure in the Workplace
Among participants reporting current full- or part-time
employment, non-disclosure in the workplace was defined
as having disclosed to ‘‘none’’ of their work colleagues.
The variables disclosure to; family/friends, a
stable partner, and the workplace, have a higher proportion
of missing values compared to the overall disclosure
variable, as a number of participants who indicated dis-
closure to at least one person did not provide information
on type of confidant, and we did not assume that a missing
answer indicated non-disclosure.
Statistical Analysis
Prevalence of disclosure was assessed overall (no one, at
least one person), by confidant (family, friends, co-work-
ers, stable partner), and extent (none, some, most or all)
among MSM, heterosexual men, and heterosexual women.
Prevalence was compared across gender/sexual orientation
groups using chi-squared tests.
We examined the association of socio-demographic and
HIV-related factors with non-disclosure in the social con-
text (versus disclosure to at least one person). As initial
analyses suggested similar patterns of associations for
heterosexual men and women, these were combined and
analyses were conducted separately for MSM and hetero-
sexual individuals. Modified Poisson regression models
with cluster-robust error variances were used to produce
unadjusted and adjusted prevalence ratios (PRs) with 95 %
confidence intervals [26]. The association of each socio-
demographic and HIV-related factor was assessed in a
separate multivariable model with adjustment for gender
(for the heterosexual analysis), age group (\30, 30–39,
40–49, 50–59, C60), ethnicity (white, black African, all
other/missing), time since HIV diagnosis (B3 months,
3 months–2 years, 2–5, 5–15, and[15 years), ART status
(on ART, not on ART), and clinic.
Modified Poisson regression was used to examine the
unadjusted and adjusted association of socio-demographic,
HIV-related, and relationship-related factors [stable part-
ner’s HIV status (HIV-positive, HIV-negative, unknown
HIV-serostatus), time in relationship (B2, 3–5, C6 years),
cohabitation with partner (yes, no)] with non-disclosure to
a partner/spouse (versus disclosure to partner), among
participants in a stable relationship. Multivariable models
included gender (for heterosexuals analysis only), age
(\50, C50 years), ethnicity (white, all other/missing), time
since HIV diagnosis (B2, 3–10, [10 years), ART status
(on or not on ART), and clinic as detailed above.
We examined the associations of two disclosure vari-
ables (overall, to friends and family) with: (1) low social
support, (2) symptoms of depression, (3) symptoms of
anxiety (4) non-adherence to ART, and (5) viral load (VL)
non-suppression among participants on ART for at least
6 months prior to the questionnaire VL measure. Modified
Poisson regression was used to examine adjusted associa-
tions; in each case the model included, in addition to the
disclosure variable, age group (\50, C50, missing), gender
(for heterosexual models only), ethnicity (white, all other/
missing), time since HIV diagnosis (\2, 2–10,[10 years),
and ART status (on ART, off ART; for social support,
depression, anxiety analyses only), and clinic. Analyses
were performed using Stata version 13.0.
Results
Study Population
During the study period 5112 HIV-diagnosed men and
women were invited to participate in ASTRA, of whom
186 AIDS Behav (2017) 21:184–195
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3258 completed the questionnaire (response rate 64 %)
[22.] The mean age was 45.2 years (SD 9.6). Men who
have sex with men accounted for 69.0 % (n = 2248) of
respondents, of whom 89.3 % identified as white. Among
heterosexual men (n = 354), 57.6 % identified as black
African/other, as did 73.6 % of women (total n = 606).
Overall, 44.6 % of MSM and 35.5 % of heterosexual
individuals had a university degree or higher. The
median time since HIV diagnosis was 9 years (IQR
4-15). Eighty-five percent of participants were currently
on ART, of whom 86.6 % had suppressed viral load
(B50 copies/mL).
Disclosure—Social Context
Information on HIV status disclosure was provided by
3233 (99.2 % of 3258 ASTRA) participants. Of these,
8.4 % (n = 272) had not disclosed their status to anyone.
There were significant differences in disclosure between
gender/sexual orientation groups. (Table 1) Prevalence of
non-disclosure was higher in heterosexual men and women
compared to MSM (16.6, 15.7, 5.0 %, respectively,
p\ 0.001). For MSM the prevalence of non-disclosure to
family members was higher than the prevalence of non-
disclosure to friends (40.1 vs. 14.2 %). The opposite
Table 1 Prevalence of HIV
status disclosure by
gender/sexual orientation and
confidant (N = 3,233)
MSM (N = 2240) Heterosexual men (N = 367) Women (N = 626)
n % n % n %
Overall disclosure status (N = 3233)
No one 113 5.0 61 16.6 98 15.7
At least one person 2127 95.0 306 83.4 528 84.3
p\ 0.001
Family members (N = 2645)
None 754 40.1 105 38.9 162 32.9
Some 613 32.6 118 43.7 233 47.3
Most or all 515 27.4 47 17.4 98 19.9
p\ 0.001
Friends (N = 2641)
None 283 14.2 133 55.9 173 42.5
Some 1110 55.6 90 37.8 200 49.1
Most or all 603 30.2 15 6.3 34 8.4
p\ 0.001
Family and friends combined (N = 2845)a
None 261 12.9 100 34.8 149 28.3
Some 1401 69.0 175 61.0 349 66.2
Most or all 369 18.2 12 4.2 29 5.5
p\ 0.001
Colleagues (N = 1400 employed)
None 621 54.2 79 84.0 135 84.4
Some 452 39.4 13 13.8 21 13.1
Most or all 73 6.4 2 2.1 4 2.5
p\ 0.001
Stable partner/spouse (N = 1631 in a relationship)
Not disclosed 54 4.9 25 10.9 38 13.0
Disclosed 1056 95.1 204 89.1 254 87.0
p\ 0.001
Information on non-disclosure overall was available for 3233 out of 3258 ASTRA participants
a Combination categories created from disclosure to friends and disclosure to family variables as follows;
none: none in both, or no answer in one and none in the other; some: some in at least one of the two
variables, or most/all in one and either no answer, none, or some in the other; most/all: both variables most/
all. Missing for 217 MSM, 86 heterosexual men, 110 women
P values by Chi squared test
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pattern was observed for heterosexuals (non-disclosure to
family 35.0 vs. to friends 47.4 %). A total of 1806 par-
ticipants were currently employed; among the 1,400 who
provided information on workplace disclosure, 84.0 % of
heterosexuals and 54.2 % of MSM reported non-disclosure
to any work colleagues.
A total of 1810 (56.1 %) participants had a stable part-
ner or spouse, of whom 1631 (90.1 %) provided informa-
tion on disclosure to partner (Table 1). Prevalence of non-
disclosure to a stable partner was much lower among MSM
(4.9 %) than among heterosexual men (10.9 %) and
women (13.0 %) (p\ 0.001).
Factors Associated with Non-Disclosure in the Social
Context
In unadjusted associations among 2240 MSM, using
modified Poisson regression models, non-disclosure in the
social context was associated with black African or other
non-white ethnicity, being religious, non UK-birth, more
recent HIV diagnosis (with a trend of lower non-disclosure
with longer time since diagnosis), not being on ART, and
not having a stable partner (p\ 0.05 for all, Table 2).
Although there was no significant trend with age in unad-
justed analysis, prevalence of non-disclosure tended to be
higher among those aged C60 years, compared to all other
age groups. Education and employment status were not
associated with non-disclosure (p[ 0.05). In multivariable
models (adjusted for age group, ethnicity, time since HIV
diagnosis, ART status, and clinic), older age, black African
and other non-white ethnicity, more recent HIV diagnosis,
and not having a stable partner were independently asso-
ciated with non-disclosure (p\ 0.05) (Table 2).
In unadjusted analyses among 993 heterosexual men and
women, black or other non-white ethnicity, more recent
HIV diagnosis, and not having a stable partner were
associated with non-disclosure (p\ 0.05 for all, Table 2);
the association with non-UK birth was of borderline sta-
tistical significance. Gender, age group, being religious,
education, employment, and ART status were not associ-
ated with non-disclosure. In multivariable modified Pois-
son models (adjusted for gender, age group, ethnicity, time
since HIV diagnosis, ART status, and clinic), older age,
black African and all other non-white ethnicity, more
recent HIV diagnosis, and not having a stable partner
remained significantly associated with non-disclosure
among heterosexual individuals. (p\ 0.05 for all).
Non-Disclosure to a Stable Partner/Spouse
Disclosure status to a stable partner was available for 1110
MSM in a stable relationship. In unadjusted analysis, non-
white ethnicity, more recent HIV diagnosis, not being on
ART, and having a stable partner of unknown HIV status
were significantly associated with non-disclosure to a
stable partner (p\ 0.05 for all, Table 3). After adjustment
for age, ethnicity, time since HIV diagnosis, ART status,
and clinic, non-white ethnicity and having a stable partner
of unknown HIV-serostatus remained significantly associ-
ated with non-disclosure to a stable partner (p\ 0.05 for
both). Associations with more recent HIV diagnosis and
not being on ART were of borderline significance. Length
of time in the current relationship and cohabitation with the
stable partner were not associated with partner non-dis-
closure among MSM.
For 527 heterosexual men and women in a stable rela-
tionship, non-disclosure to a partner was associated with
having a stable partner of unknown HIV status, shorter
duration of relationship, and not cohabitating with the
stable partner in unadjusted analysis.(p\ 0.05 for all,
Table 3) These associations were similar or slightly
attenuated in the multivariable models (adjusted for gen-
der, age group, ethnicity, time since HIV diagnosis, ART
status, and clinic); having a stable partner of unknown HIV
status and cohabitation remained significantly associated
with non-disclosure, and shorter duration of relationship
was of borderline significance.
Levels of Non-Disclosure and Association
with Social Support, Psychological Symptoms, ART
Non-Adherence, and Virological Non-Suppression
on ART
Figure 1 shows the prevalence of the dependent variables
under study for MSM and heterosexual individuals. There
was no significant difference in the prevalence of low
social support, depressive or anxiety symptoms between
MSM and heterosexuals (p[ 0.05 for all, Chi squared
test). Compared to MSM, heterosexual men and women
had higher prevalence of non-adherence to ART (35.0 %
vs. 30.2 %, p\ 0.05) and of viral load non-suppression on
ART (12.6 vs. 8.3 %, p\ 0.05).
Figure 1 also shows adjusted associations between
overall non-disclosure versus disclosure to at least one
other person among MSM and heterosexuals. Among
MSM, overall non-disclosure was not significantly associ-
ated with low social support, depression or anxiety symp-
toms, ART non-adherence, or viral load non-suppression,
in unadjusted or adjusted analyses (multivariable models
adjusted for age group, ethnicity, time since HIV diagnosis,
clinic, and ART status—for social support, depression,
anxiety analyses only).
There was some evidence to suggest that MSM who had
disclosed to ‘most or all’ friends and family were more
likely than those who had disclosed to ‘some’ or ‘no’
friends or family to report depression (PR compared to
188 AIDS Behav (2017) 21:184–195
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‘some’ disclosure = 1.4, 95 % CI 1.2–1.7), anxiety (1.3,
1.1–1.6), and ART non-adherence (1.3, 1.1–1.5) (Fig. 2).
For heterosexual men and women, non-disclosure
(overall, and level of disclosure to friends and family) was
not significantly associated with low social support,
depression or anxiety symptoms, ART non-adherence, or
viral load non-suppression in unadjusted or adjusted anal-
yses (Figs. 1 and 2).
Discussion
In this large multicentre cross-sectional study of 3258
people with diagnosed HIV, the prevalence of non-dis-
closure of HIV status was overall low, but was about three
times higher among heterosexual men and women com-
pared to MSM. Non-disclosure was not significantly
associated with adverse psychological symptoms, ART
non-adherence, or virological non-suppression on ART
among MSM or heterosexual individuals.
The prevalence of non-disclosure was higher among
heterosexuals of black African or other non-white ethnic-
ity, a pattern corroborated in smaller UK studies
[2, 6, 11, 14]. The effect of ethnicity was also apparent
among MSM. These ethnic differences, coupled with
higher non-disclosure in non UK-born MSM and hetero-
sexuals, may reflect cultural drivers of non-disclosure
operating among ethnic minority or migrant populations
who may experience perceived or enacted stigma [11, 20].
Attention should be directed to demographic groups with
highest non-disclosure so as to better understand circum-
stances that encourage or discourage it.
The association between age and non-disclosure varies
across study context and confidant; in an earlier UK study
of 982 white MSM and black African heterosexual men
attending HIV clinics, older age was associated with higher
non-disclosure to family [11]; two other studies with pre-
dominantly black populations (270 clinic attendees in
Tanzania, and 269 in southern USA) [8, 10] found the
opposite trend, with older participants being more likely to
disclose to anyone, including their stable partner. Another
US study of 362 young (\24 years) racial minority MSM
not in care or newly HIV-diagnosed, found no association
between age and non-disclosure of HIV status [7]. In our
study, older participants (C60 years) had higher prevalence
of overall non-disclosure. It is possible that older people
experience or perceive a greater level of stigma sur-
rounding HIV disclosure than younger people [27]. On the
other hand, older people may feel able to better manage
HIV without disclosing. Although a higher proportion of
older people were diagnosed in the earlier years of the
epidemic when prognosis was poor and HIV-related stigma
was likely to be greater, this seems unlikely to explain theT
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Fig. 1 Adjusted associations (prevalence ratios 95 % CIs) between
overall non-disclosure and: social support, depressive symptoms,
anxiety symptoms, ART non-adherence, and viral load non-suppres-
sion on ART, among 2240 MSM (left panel) and 993 heterosexual
men and women (right panel). PR prevalence ratio, CI confidence
interval; multivariable modified Poisson models included gender (for
heterosexuals only), age group (\50, C50, missing), ethnicity (white,
all other), time since HIV diagnosis (\2, 2–10,[10 years), clinic, and
ART status (on ART, off ART; for social support, depression, anxiety
analyses only); p-values by Wald test; Non-adherence defined as:
missed C1 ART dose in the past 2 weeks or missed C2 consecutive
days of ART on more than 1 occasion in the past 3 months; Viral load
non-suppression defined as viral load[50 c/mL among those on ART
for at least 6 months: n = 1669 MSM, n = 742 heterosexual men and
women
Fig. 2 Adjusted associations (prevalence ratios 95 % CIs) between
levels of disclosure to friends and family combined and: social
support, depressive symptoms, anxiety symptoms, ART non-adher-
ence, and viral load non-suppression on ART, among 2031 MSM (left
panel) and 814 heterosexual men and women (right panel). PR
prevalence ratio; CI confidence interval; multivariable modified
Poisson models included gender (for heterosexuals only), age group
(\50, C50, missing), ethnicity (white, all other), time since HIV
diagnosis (\2, 2–10,[10 years), ART status (on ART, off ART; for
social support, depression, anxiety analyses only), and clinic; p values
by Wald test; non-adherence defined as: missed C1 ART dose in the
past 2 weeks or missed C2 consecutive days of ART on more than 1
occasion in the past 3 months; viral load non-suppression defined as
viral load [50 c/mL among those on ART for at least 6 months:
n = 1489 MSM, n = 605 heterosexuals; combination categories
created from disclosure to friends and to family variables as follows;
none: none in both, or no answer in one and none in the other; some:
some in at least one of the two variables, or most/all in one and either
no answer, none, or some in the other; most/all: both variables most/
all. Missing for n = 209 MSM, n = 179 heterosexuals. (Prevalence
of outcomes in MSM and heterosexuals with missing values in
variable disclosure to friends and family was: low social support
12.4 % in MSM, 11.7 % in heterosexual men and women; depression
30.6, 21.2; anxiety 24.9,19.0 %; ART non-adherence 28.2, 26.8 %;
viral load non-suppression 11.0, 11.3 %)
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age association, as an effect of older age was apparent after
adjustment for time since HIV diagnosis. In fact, in line
with other studies [1, 12, 14, 27], shorter time since diag-
nosis was independently associated with non-disclosure for
MSM and heterosexuals in ASTRA, suggesting that dis-
closure of HIV status is a gradual process. This finding may
highlight the need for health professionals to provide a
supportive context soon after diagnosis and to assist in
building communication and coping strategies for those
who need them. Even though participants not on ART
tended to have higher levels of non-disclosure, these
associations were explained by shorter time since HIV
diagnosis and were not significant in multivariable models.
Socio-economic factors such as education and employment
status were not associated with non-disclosure among
MSM or heterosexuals.
Although gender/sexual orientation differences in the
pattern and levels in social disclosure are documented, few
studies have investigated these in the context of disclosure to
a stable partner/spouse [9]. In ASTRA, non-disclosure to a
stable partner was more than twice as high among hetero-
sexuals as among MSM. In line with previous studies
[3, 28, 29], our analysis showed that participants who did not
know their stable partner’s HIV-serostatus were more likely
to have not disclosed their own serostatus, which is likely to
reflect the dynamics of mutual disclosure. Longer length of
time in the relationship and cohabitation were significantly
associatedwith greater levels of disclosure to a stable partner
among heterosexuals; previous studies among black African
heterosexual women in the UK and Tanzania found similar
results [5, 11], but there is little information on heterosexual
men and MSM from the UK. Among MSM in our study,
levels of disclosure to a stable partner did not vary according
to cohabitation or time in relationship, which may reflect
differences in patterns of partnerships and/or sexual rela-
tionships among MSM.
The majority of employed participants had not-disclosed
to any co-workers, with much higher non-disclosure among
heterosexual men and women (84 % in each case). Dis-
crimination against people living with HIV in the work-
place is unlawful in the UK [30]. However, the high
prevalence of non-disclosure to work colleagues in this
sample may be due to prevailing fear of harassment and
breach of privacy, or may reflect personal choice regarding
disclosure confidants. We highlight the need for employers
to enact clear policies, which demonstrate commitment to
confidentiality and non-discrimination of HIV-diagnosed
employees.
While the therapeutic effect of disclosure as a means of
accessing social support has been promoted [9,] evidence
on the association between disclosure and measures of
mental health status remains mixed. A systematic review of
31 US studies among young (\25 years) people living with
HIV found that disclosure was positively associated with
higher social support, although younger age may itself be
associated with more readily available sources of social
support, such as parents, siblings, schoolmates [12]. Sim-
ilarly, in the international cross-sectional ELLA study
(2012–2013) of 1931 HIV-diagnosed women, 11 % had
not disclosed to anyone; non-disclosure was significantly
associated with lack of social support from family and
friends and higher scoring on a scale of severity of barriers
to HIV care (BACS). The BACS included measures of lack
of psychological support, mental health problems, and
stigma [16]. The high prevalence of perceived stigma
(78 %) and lack of regular social support (40 %) in ELLA
may account for the association between non-disclosure
and mental health outcomes, but the relationship may be
bidirectional; pre-existing depression and anxiety may
predispose individuals to non-disclosure [16]. Conversely,
two earlier small cross-sectional studies from the UK (one
among 45 black African men and women attending sexual
health clinics [2] and one among 95 majority white male
HIV outpatient clinic attendees [14]) did not find any
association between non-disclosure and social support, but
power to examine associations was limited. In our larger
study, there was little evidence that individuals who had
not disclosed their HIV status were more likely to have low
social support or experience psychological symptoms, than
those who had disclosed.
Few studies have investigated the association between
non-disclosure and ART non-adherence or virological
suppression. Our results are similar to those from two
previous studies from Canada and the UK showing a lack
of an association with non-adherence [20, 31]. In our study,
non-disclosure was also not associated with virological
non-suppression among MSM or heterosexuals. The lack of
association may partly reflect the relative ease of good
adherence to current ART without the need to disclose, due
to simpler regimens available and lower ART toxicity, or
good support from medical teams independent of social
disclosure. These findings also appear consistent with the
lack of association between non-disclosure and psycho-
logical symptoms.
When considering level of disclosure to family and
friends among MSM, we found some evidence to suggest
that prevalence of depression, anxiety, and ART non-ad-
herence was higher among the relatively small group with
high levels of social disclosure compared to those with
moderate or no social disclosure. This finding may allude
to potential negative consequences of widespread disclo-
sure such as discrimination or rejection from family
members and friends. Lower levels of social disclosure
could be indicative of a more successful strategy of
selecting confidants most likely to provide support and a
positive experience of disclosure.
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ASTRA is the largest multicentre questionnaire study
undertaken among HIV-outpatients in the UK to date,
giving reasonable statistical power to examine associations
with a factor of low prevalence, such as non-disclosure.
However, for our analysis of non-disclosure and viral non-
suppression, confidence intervals are wide due to the low
prevalence of both factors. Prevalence of non-disclosure
may be influenced by non-response; if non-disclosure was
more prevalent among those who refused study participa-
tion, then our study would underestimate non-disclosure.
There was a significant proportion of missing data for the
disclosure category sub-questions, but not for the overall
non-disclosure question on which our primary analyses are
based. In addition, it was not possible from the question
wording to ascertain whether disclosure to a stable partner
was to the current stable partner, a previous/concurrent
partner, or a casual partner, which could underestimate
prevalence of non-disclosure to the current partner. To
increase the validity of the stable partner non-disclosure
measure we restricted the measure to those who reported
being in an ongoing relationship only. Due to restricted
sample size of those with a stable partner, it was not pos-
sible to examine the associations between non-disclosure to
a stable partner and measures of social support, mental
health, ART adherence, and viral load suppression. We did
not include a measure of stigma in the questionnaire, which
may have shed further light on associations with non-dis-
closure. Finally, it should be emphasised that, while epi-
demiological studies such as ours provide insight into
patterns of non-disclosure among a clinic-based popula-
tion, they are not able to capture the complex circum-
stances, motivations, and challenges that may surround the
issue of disclosure for an HIV-positive individual.
In conclusion, we found that the prevalence of non-
disclosure of HIV status to the social circle was overall
low, and higher among heterosexuals than MSM. Non-
disclosure to anyone in the social network was not asso-
ciated with higher prevalence of low social support,
depression or anxiety symptoms, non-adherence to ART, or
viral load non-suppression on ART, suggesting that
choosing not to disclose may be a way of coping and is not
necessarily linked to adverse psychological consequences
or difficulty in managing treatment. These findings are
encouraging and may be useful in informing discussions
between patients and healthcare professionals about dis-
closure and ART adherence, and about support available to
those who choose not to disclose their status.
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